Mepacrine therapy in niclosamide resistant taeniasis.
OBJECTIVE
To evaluate the efficacy of mepacrine (quinacrine) in patients with niclosamide resistant Taenia saginata infection.


METHODS
Eighty six cases with niclosamide resistant Taenia saginata (unresponsive to 2-8 courses of niclosamide) were treated with quinacrine (1 g) administered orally or via a nasogastric tube, and followed at 2, 4, 8 and 12 weeks for recurrence of passage of proglottids and presence of Taenia eggs in the stool examinations. Pre and post-therapy egg counts were obtained and egg viability was tested by staining with methylene blue.


RESULTS
Eighty-one (94.2%) patients responded promptly with passage of the worm within 4-72 hours. The egg counts showed a drastic fall in 79 cases and a fall in viability from a median of 100% to 0% was observed. Only one patient demonstrated a relapse at 4 weeks. Gastrointestinal side effects occurred in 9 cases but were controlled easily by symptomatic therapy.


CONCLUSIONS
We conclude that quinacrine is a safe, inexpensive, effective and generally well tolerated drug for the treatment of niclosamide resistant Taenia saginata infestations.
Department of Internal Medicine, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir.
P A
PA
Koul
A
A
Wahid
M H
MH
Bhat
J I
JI
Wani
B A
BA
Sofi
D000293:Adolescent; D000328:Adult; D000923:Anticestodal Agents / Q000627:therapeutic use*; D002648:Child; D003551:Cysticercosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009534:Niclosamide / Q000627:therapeutic use; D011796:Quinacrine / Q000627:therapeutic use*; D016896:Treatment Outcome
D000923:Anticestodal Agents; D009534:Niclosamide; D011796:Quinacrine